News

The AAC reviewed safety and efficacy data from the pivotal Phase III combination therapy programme trials, representing the largest clinical trial data set of gout patients treated with

The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. Janssen has optioned 11 programs out of a total of 20 programs under the

The technology provides targeted release of gastric acid- and heat-sensitive active ingredients to the upper gastrointestinal tract. It allows oral delivery of several compounds, including vaccines, proteins and

ondelis is approved for patients with two forms of STS, liposarcoma or leiomyosarcoma, who had earlier received chemotherapy that contained anthracycline. While it is approved for both leiomyosarcoma

The company received a complete response letter, which the FDA sends to a company to inform that the marketing application will not be approved in its existing form.

Imlygic, also known as talimogene laherparepvec (T-Vec), is recommended to treat adults with unresectable melanoma that is regionally or distantly metastatic with no bone, brain, lung or other

In total, the actions are expected to add incremental benefits of $175m when the full run rate of the plan is achieved. With the inclusion of approximately $0.153

Professor David E. Thurston of the Institute of Pharmaceutical Science will lead a team at King’s to develop and optimize a range of specific small molecules for Auris

Strensiq, an innovative enzyme replacement therapy (ERT), is the first therapy approved in the U.S. for the treatment of patients with HPP, a genetic, chronic, and progressive ultra-rare